Trial Profile
Conversion From Immediate Release Tacrolimus to Envarsus XR in Simultaneous Pancreas-Kidney Recipients: Assessment of Functional, Safety and Quality of Life Outcomes (CIRTEN SPK)
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Kidney-pancreas transplant rejection
- Focus Adverse reactions; Therapeutic Use
- Acronyms CIRTEN SPK
- 26 Jan 2024 Planned End Date changed from 31 Dec 2024 to 1 Dec 2025.
- 26 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 1 Dec 2025.
- 05 Apr 2022 Planned End Date changed from 31 Oct 2022 to 31 Dec 2024.